XML 68 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE - Contract Assets and Liabilities (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended 48 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2018
Dec. 31, 2021
Jan. 31, 2018
Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contract asset $ 32,051,000   $ 32,051,000         $ 0
Net revenues 77,493,000 $ 95,413,000 269,171,000 $ 286,317,000        
Royalties and milestones                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Net revenues 20,277,000 $ 209,000 25,784,000 $ 596,000        
Collegium Pharmaceutical Inc                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contract liability             $ 10,000,000  
Contract asset 32,051,000   32,051,000         $ 0
Grunenthal | Royalties and milestones | Commercialization agreement, net                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Increase in royalties obligation 10,800,000   25,200,000          
Grunenthal | Maximum | Forecast                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Royalty obligation           $ 9,000,000    
Grunenthal | Royalties and milestones | Commercialization agreement, net                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Net revenues 7,100,000   21,500,000          
NUCYNTA products | Grunenthal | Royalties and milestones | Commercialization agreement, net                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Royalty revenue recognized 3,700,000              
NUCYNTA products | Grunenthal | Minimum | Forecast                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Net revenues           180,000,000    
NUCYNTA products | Grunenthal | Maximum | Forecast                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Net revenues           243,000,000    
NUCYNTA products | Collegium Pharmaceutical Inc | Grunenthal | Minimum | Forecast                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Royalty obligation         $ 34,000,000 $ 34,000,000    
Prepaid and other current assets                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contract asset 9,900,000   9,900,000          
Other long-term assets                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contract asset $ 22,100,000   $ 22,100,000